The outcome of diabetes treatments can and should be evaluated through the patients' treatment satisfaction. The aim of this study was to examine the patients' satisfaction with the therapy with human insulin analogues compared with previous treatment with human insulin. We evaluated patient satisfaction in patients with T1DM in our institution who were currently on IIT with human insulins. We performed testing with standard World Health Organization Diabetes Treatment Satisfaction Questionnaire (WHO DTSQ) before and after the therapy with insulin analogs. The overall DTSQ score in forty-nine patients after the third month of therapy and after the sixth month of therapy is higher than before the initiation of therapy (p < 0.001). The results of the responses on the perception of hyperglycaemia were lower after three months of therapy (p < 0.05) and after the six months of treatment than before the onset of therapy (p < 0.01). There were no differences in the perception of hypoglycaemia after three months; however, perception of hypoglycaemia after the sixth month of treatment was lower than before the onset of therapy (p < 0.001) and compared to the score after the third month of therapy (p < 0.01). Therapy of T1DM patients with insulin analogue aspart over three months led to an increase in satisfaction with therapy and a reduction of the perception of hyperglycaemia. Therapy of T1DM patients with insulin analogues (aspart and glargine) over three months led to an increase in satisfaction with therapy and a reduction of the perception of both hyperglycaemia and hypoglycamia.
References
1.
Garg S, Moser E, Dain MP, Rodionova A. Clinical Experience with Insulin Glargine in Type 1 Diabetes. Diabetes Technology & Therapeutics. 2010;12(11):835–46.
2.
Bradley C, Gilbride CJB. Improving treatment satisfaction and other patient‐reported outcomes in people with type 2 diabetes: the role of once‐daily insulin glargine. Diabetes, Obesity and Metabolism. 2008;10(s2):50–65.
3.
Kotsanos JG, Vignati L, Huster W, Andrejasich C, Boggs MB, Jacobson AM, et al. Health-Related Quality-of-Life Results From Multinational Clinical Trials of Insulin Lispro: Assessing benefits of a new diabetes therapy. Diabetes Care. 1997;20(6):948–58.
4.
Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabetic Medicine. 2000;17(11):762–70.
5.
Tamás Gy, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Research and Clinical Practice. 2001;54(2):105–14.
6.
Sheldon B, Russell‐Jones D, Wright J. Insulin analogues: an example of applied medical science. Diabetes, Obesity and Metabolism. 2009;11(1):5–19.
7.
Bradley C, Speight J. Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes/Metabolism Research and Reviews. 2002;18(S3):S64–9.
8.
Bradley C, Gamsu DS. Guidelines for Encouraging Psychological Well‐being. Diabetic Medicine. 1994;11(5):510–6.
9.
Biderman A, Noff E, Harris SB, Friedman N, Levy A. Treatment satisfaction of diabetic patients: what are the contributing factors? Family Practice. 26(2):102–8.
10.
Boyle JP, Honeycutt AA, Narayan KMV, Hoerger TJ, Geiss LS, Chen H, et al. Projection of Diabetes Burden Through 2050. Diabetes Care. 2001;24(11):1936–40.
11.
Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42(10):1151–67.
12.
Hirsch IB. Insulin Analogues. New England Journal of Medicine. 2005;352(2):174–83.
13.
Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, et al. Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulin. Diabetic Medicine. 2004;21(11):1213–20.
14.
Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross‐over trial in people with Type 1 diabetes. Diabetic Medicine. 2006;23(3):285–92.
15.
Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23(5):583–8.
16.
DeWitt DE, Hirsch IB. Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus. JAMA. 2003;289(17):2254.
17.
Home PD. Intensive insulin therapy in clinical practice. Diabetologia. 1997;40(14):S83–7.
18.
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine. 1993;329(14):977–86.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
